Latest news

Maritech® fucoidan research part of $270M R&D boost

Scientists in lab smiling

Australia has made a bold move to supercharge its dynamic marine bioproducts industry by announcing a $270M, decade-long R&D program.

The Marine Bioproducts Cooperative Research Centre (MB-CRC) is a $270M consortium of 68 partners led by Flinders University. It will fast-track the growth of Australia’s next generation of marine bio-industries to meet rapidly growing global demand for certified, safe and sustainable products including plant-based proteins, nutraceuticals, omega 3 oils, cosmetics, agrochemicals, bioplastics and more. 

“Marinova is proud to be a part of this innovative consortium of industry, government and academic partners,” said company CEO & Managing Director, Mr Paul Garrott. “Australia is increasingly being recognized as a world leader in the research and manufacture of high value marine bioproducts. The collaborations that will result from the MB-CRC will drive innovative new research projects and further enhance this country’s global reputation. We look forward to working alongside partners who not only share our passion for improved health outcomes but also our vision for an expansive - and sustainable - marine bioproducts sector in Australia. The future opportunities for superior algal-derived products here are huge.”

“Marinova’s involvement in the MB-CRC will fast-track a number of very significant research projects that we have planned for our unique fucoidan extracts,” continued Mr Garrott. “Maritech® fucoidan is the world’s only high purity, certified organic fucoidan with global regulatory acceptance. We expect enormous commercial opportunities to emerge from expanding our research program, particularly in the areas of immune modulation, viral inhibition, gut & digestive health, anti-cancer, anti-inflammation and anti-ageing."

Australia’s rapidly growing marine biotech industry is supported by the world’s third largest marine area. Current estimates suggest the country’s high quality marine bioproducts are on track to reach $1 billion turnover by 2030.

Further details are available on the MB-CRC website. 

Previous Next

News index